Avandia raises heart attack risk: NEJM analysis
GlaxoSmithKline’s Type-2 diabetes treatment Avandia (rosiglitazone) “significantly increases” the risk of heart attacks, according to an analysis of studies published yesterday on the Web site of The New England Journal of Medicine.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.